Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $7.00 target price on the stock.

A number of other research analysts have also weighed in on KPTI. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Piper Sandler upped their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 5.9 %

NASDAQ KPTI opened at $0.63 on Wednesday. The stock’s 50-day moving average price is $0.76 and its 200-day moving average price is $0.81. The company has a market capitalization of $79.90 million, a P/E ratio of -0.56 and a beta of 0.07. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to analysts’ expectations of $37.86 million. During the same period last year, the firm posted ($0.30) EPS. Research analysts anticipate that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new stake in shares of Karyopharm Therapeutics in the second quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $167,000. Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the last quarter. Finally, FMR LLC grew its position in Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).